These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37982229)

  • 21. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
    Ning L; Lang J; Wu L
    BMC Cancer; 2022 Jan; 22(1):6. PubMed ID: 34980005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary interleukin-1β levels among gynecological patients.
    Woolery KT; Hoffman MS; Kraft J; Nicosia SV; Kumar A; Kruk PA
    J Ovarian Res; 2014 Nov; 7():104. PubMed ID: 25403235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
    Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
    Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.
    Lee YH; Kim JH; Zhou H; Kim BW; Wong DT
    J Mol Med (Berl); 2012 Apr; 90(4):427-34. PubMed ID: 22095100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum microRNA-145 as a novel biomarker in human ovarian cancer.
    Liang H; Jiang Z; Xie G; Lu Y
    Tumour Biol; 2015 Jul; 36(7):5305-13. PubMed ID: 25722112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
    Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
    Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
    Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
    Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients.
    Chen L; Yao Y; Sun L; Zhou J; Liu J; Wang J; Li J; Tang J
    J Ovarian Res; 2015 Nov; 8():78. PubMed ID: 26589590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteopontin as a potential diagnostic biomarker for ovarian cancer.
    Kim JH; Skates SJ; Uede T; Wong KK; Schorge JO; Feltmate CM; Berkowitz RS; Cramer DW; Mok SC
    JAMA; 2002 Apr; 287(13):1671-9. PubMed ID: 11926891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
    Tamir A; Jag U; Sarojini S; Schindewolf C; Tanaka T; Gharbaran R; Patel H; Sood A; Hu W; Patwa R; Blake P; Chirina P; Oh Jeong J; Lim H; Goy A; Pecora A; Suh KS
    J Ovarian Res; 2014 Dec; 7():109. PubMed ID: 25477184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer.
    Pothacharoen P; Siriaunkgul S; Ong-Chai S; Supabandhu J; Kumja P; Wanaphirak C; Sugahara K; Hardingham T; Kongtawelert P
    J Biochem; 2006 Oct; 140(4):517-24. PubMed ID: 16936295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.
    Ali FT; Soliman RM; Hassan NS; Ibrahim AM; El-Gizawy MM; Mandoh AAY; Ibrahim EA
    PLoS One; 2022; 17(8):e0272308. PubMed ID: 35921382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.